key: cord-0751572-ita7hlca
authors: Furukawa, Fumina; Makino, Teruhiko; Torai, Ryotaro; Mori, Shuichi; Terada, Yoshiyuki; Seki, Taiki; Shimizu, Tadamichi
title: Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides
date: 2021-11-08
journal: Eur J Dermatol
DOI: 10.1684/ejd.2021.4085
sha: ecdbb18edb340305262650c46f2ac1572a0216a9
doc_id: 751572
cord_uid: ita7hlca

nan

Folliculotoropic mycosis fungoides (MF) is a variant of MF, that clinically shows acneiform or follicular keratosis-pilaris-like lesions on the head and neck, which histologically shows selective infiltration of atypical lymphocytes in the follicular epithelium. Folliculotropic MF shows a more aggressive clinical course in comparison to classic MF [1] . In a recent study, folliculotropic MF was classified into two distinct patterns: an early variant and an advanced tumour variant. The prognostic implications differ, with the early variant following a more indolent course [2] . In an excimer laser, the dissociation of xenon and chloride gases creates a 308-nm monochromatic light, which suppresses T lymphocyte proliferation via the induction of apoptosis [3] . The effectiveness of excimer laser for classic MF has been reported [4] . We herein report a patient with advanced stage folliculotropic MF, who was successfully treated with a combination of bexarotene and excimer laser therapy. A 58-year-old Japanese man presented to our hospital with a skin lesion that had persisted for three months. A physical examination revealed several tumours on his head and face (figure 1A) and erythema with follicular accentuation on his back, abdomen and upper extremities (figure 1B) . A histological examination of a tissue specimen obtained from a head nodule revealed infiltration of atypical small cells around the hair follicles (figure 1C) and prominent folloculotropism. (figure 1 D) . Immunohistochemically, the atypical cells were positive for CD3 and CD4 ( figure 1E ). Clonal rearrangement of the T-cell receptor gene of lymphocytes that had infiltrated into the skin was detected. Blood test findings were almost within normal limits. No atypical lymphocytes were detected. Soluble interleukin-2 receptor level was not elevated (378 U/mL). HTLV-I antibodies were not detected. No lymph node or internal organ abnormalities were detected on positron emission tomography-computed tomography. No bone marrow involvement was observed. Accordingly, the patient was diagnosed with folliculotropic MF (T3N0M0, Stage-b). The patient was initially treated with topical steroids and bexarotene (300 mg/m 2 ). Two weeks later, the skin lesions on the trunk showed slight improvement; however, the tumours showed no change. Therefore, irradiation using an excimer laser (XTRAC ® velocity7; STRATA Skin Sciences, Inc., PA) was performed for the remaining erythema and tumours on the face, head and trunk (200 mJ/cm 2 , three times/week). Thereafter, the skin lesions gradually improved, and completely disappeared at 10 weeks ( figure 1F, G) . No side effects, except for slight erythema, were observed. The bexaroten and excimer laser treatment (200 mJ/cm 2 , twice/month) has been continued as maintenance therapy without signs of relapse.

In the present patient, combination therapy with bexarotene and excimer laser treatment was effective for both the erythema on the trunk and the tumour on the face and head. Skin-directed therapy, such as psoralen plus ultraviolet A (PUVA), is recommended for the initial treatment of early-stage folliculotropic MF. Radiotherapy, oral retinoids or systemic chemotherapy are commonly required for the treatment of advanced stage folliculotropic MF [5] . Bexarotene (synthetic retinoid X receptor agonist) is approved for the treatment of cutaneous T cell lymphoma. Single cases in which folliculotropic MF was successfully treated with bexarotene have been reported, mostly involving combination therapy with interferon alpha or radiotherapy [6, 7] . Combination therapy with bexarotene and PUVA was also reported to induce a good response in a case of folliculotropic MF [8] . The XTRAC ® velocity7 excimer laser delivers coherent, monochromatic short-pulse radiation through a hand-held device with a 20 × 20 mm circular spot size. It can emit a high-intensity laser beam (83,000 W/cm 2 ) by pulsed oscillation. This enables the delivery of higher fluence to deep skin lesions, resulting in the induction of apoptosis of tumour cells [9] . Furthermore, exposure of healthy skin to UV radiation may be avoided by targeted phototherapy using excimer laser [9] . In addition, we hypothesized that combination therapy with bexarotene and excimer laser treatment might have a synergistic effect, as combination therapy with bexarotene and PUVA tended to be more effective for classic MF at an early stage and led to a complete clinical response with fewer PUVA sessions using a lower PUVA dose compared to PUVA monotherapy [10] . Given the above, this combination therapy may be a useful therapeutic option for folliculotropic MF, although further research will be required to clarify the effectiveness of this therapy.

Disclosures. Financial support: none. Conflicts of interest: none. 

Folliculotropic mycosis fungoides: single-center study and systematic review

New insights into folliculotropic mycosis fungoides (FMF): A single-center experience

Applications of the excimer laser: a review

Excimer laser in the treatment of mycosis fungoides

Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch cutaneous lymphoma group

Low-dose oral bexarotene in combination with lowdose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms

Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation: successful treatment using radiation therapy plus oral bexarotene combination therapy

Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA

308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides

Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)

We report a case of cutaneous manifestations of severe COVID-19 infection in a Japanese patient, a 60-year-old woman with no significant medical history. She arrived at the referring hospital with a 10-day history of fever, cough, olfactory disturbance, and respiratory distress. A nasopharyngeal swab test for SARS-CoV-2 RNA amplification was positive. She was referred to our hospital, and remdesivir (Day 1: 200 mg/day; Days 2-5: 100 mg/day), ceftriaxone (2 g/day), and methylprednisolone (60 mg/day) were administered. Additionally, continuous hemodiafiltration and endotoxin adsorption therapy were performed. However, her condition worsened, and extracorporeal membrane oxygenation was initiated on the nineth day post-admission. On the eleventh day

SARS-CoV-2 envelope and spike protein

Laboratory tests revealed abnormalities in coagulation/fibrinolysis: 95,000 platelets/L (normal: 158,000-348,000 platelets/L), 22.3 g/mL fibrinogen/fibrin degradation products (normal: ≤ 5.0 g/mL), and 11.8 g/mL D-dimer (normal: ≤ 1.0 g/mL). In addition, monoclonal IgM and cryoglobulin were not detected. The eruptions gradually improved

COVID-19-related skin manifestations with livedo/ necrosis have been reported as relatively rare (6%), occurring transiently